The use of proteins and peptides-based therapy in managing and preventing pathogenic viruses
EM El-Fakharany, H El-Gendi, AK Saleh… - International Journal of …, 2024 - Elsevier
Therapeutic proteins have been employed for centuries and reached approximately 50% of
all drugs investigated. By 2023, they represented one of the top 10 largest-selling pharma …
all drugs investigated. By 2023, they represented one of the top 10 largest-selling pharma …
Therapeutic targeting of angiopoietins in tumor angiogenesis and cancer development
The formation and progression of tumors in humans are linked to the abnormal development
of new blood vessels known as neo-angiogenesis. Angiogenesis is a broad word that …
of new blood vessels known as neo-angiogenesis. Angiogenesis is a broad word that …
Monoclonal Antibody Biosimilars for Cancer Treatment
LN Broer, DG Knapen, DJA de Groot, PGM Mol… - iScience, 2024 - cell.com
Monoclonal antibodies are important cancer medicines. European Medicines Agency (EMA)
approved 40 and Food and Drug Administration (FDA) 48 anticancer monoclonal antibody …
approved 40 and Food and Drug Administration (FDA) 48 anticancer monoclonal antibody …
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males
B Vogg, J Poetzl, R El Galta, R Fuhr… - Expert Opinion on …, 2024 - Taylor & Francis
ABSTRACT Background This Phase I study compared the pharmacokinetic (PK) and
pharmacodynamic (PD) similarity of GP2411 proposed denosumab biosimilar to reference …
pharmacodynamic (PD) similarity of GP2411 proposed denosumab biosimilar to reference …
The emerging role of non-coding RNAs in the Wnt/β-catenin signaling pathway in Prostate Cancer
Prostate cancer (PCa) is an important worldwide medical concern, necessitating a greater
understanding of the molecular processes driving its development. The Wnt/-catenin …
understanding of the molecular processes driving its development. The Wnt/-catenin …
[HTML][HTML] Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments
This research is based on three fundamental aspects of successful biosimilar development
in the challenging biopharmaceutical market. First, biosimilar regulations in eight selected …
in the challenging biopharmaceutical market. First, biosimilar regulations in eight selected …
[HTML][HTML] Enhancing drug related problem (DRP) management in Indian healthcare through AI integration: An insight view
SK Das, RA Maheshwari, J Chakraborty, SD Roy… - Intelligent …, 2023 - Elsevier
Abstract The integration of Artificial Intelligence (AI) technologies in Indian healthcare is set
to revolutionize drug related problem (DRP) management, ensuring patient safety and …
to revolutionize drug related problem (DRP) management, ensuring patient safety and …
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics
A Tandulje, P Varpe, P Chaugule, RS Raghuvanshi… - Seminars in …, 2024 - Elsevier
Biological oncology agents are vital in cancer care, but their exorbitant expenses present
obstacles for patients, families, healthcare professionals, and insurance providers. The …
obstacles for patients, families, healthcare professionals, and insurance providers. The …
Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer
AP Mitchell, D Nemirovsky, A Mishra Meza… - JCO Oncology …, 2024 - ascopubs.org
PURPOSE Bone-modifying agents (BMAs) do not prevent skeletal-related events among
patients with castration-sensitive prostate cancer (CSPC), but many patients receive BMAs …
patients with castration-sensitive prostate cancer (CSPC), but many patients receive BMAs …
[HTML][HTML] QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a …
QY Zhang, RG Cai, GH Song, CJ Li, BH Zhang… - ESMO open, 2024 - Elsevier
Background QL1701 is a proposed biosimilar to the reference trastuzumab (Herceptin®).
This trial compared the efficacy and safety of QL1701 with the reference trastuzumab in first …
This trial compared the efficacy and safety of QL1701 with the reference trastuzumab in first …